For cancers with KRAS mutations, it is established that mtDNA release into the cytoplasm can activate STING, and suppression of STING has been linked to immune evasion in lung-cancer cells with KRAS mutations (in vitro and in SCID mice with xenografted human lung adenocarcinoma A549 cells) [240]. This evidence concerns the gene KRAS and lung adenocarcinoma.